Search
241 results found for “Online PEGACPLSA88V1 Bootcamps 💺 New PEGACPLSA88V1 Test Dumps 🦡 PEGACPLSA88V1 Latest Examprep 🧘 Download ⏩ PEGACPLSA88V1 ⏪ for free by simply entering ➽ www.pdfvce.com 🢪 website 🐠Lab PEGACPLSA88V1 Questions”
Use of High Throughput SPR to Characterize Antibodies To Common Cancer Biomarkers
https://carterra-bio.com/resources/use-of-high-throughput-spr-to-characterize-antibodies-to-common-cancer-biomarkers/Presented by: As a disease of misregulation, cancer is characterized both genetically and proteomically, requiring high quality tools to dissect the change difference between cell states. Among the reagents used…
Product Overview
https://carterra-bio.com/product-overview/HT-SPR technology with options Our platforms can transform your label-free characterization workflow allowing screening and characterization, for both large and small molecules, in a single step. Check them out! LSA…
Increasing FcγR Characterization Throughput for Drug Candidates Using LSAXT
https://carterra-bio.com/resources/increasing-fc%ce%b3r-characterization-throughput-for-drug-candidates-using-lsaxt/Key Highlights Rigorous characterization of FcγR binding is a key step required in the development of Fc-formatted therapeutics. The historical throughput limitations of real-time, label-free biosensors have resulted in challenges…
Antibody Discovery and Development for COVID-19 Diagnostic Testing – August 19, 2020
https://carterra-bio.com/resources/antibody-discovery-and-development-for-covid-19-diagnostic-testing-august-19-2020/…its proprietary platform to produce and discover highly specific antibodies against SARS-CoV-2 proteins, which can be used for developing a diagnostic testing product. Learn how Twist Biopharma uses the Carterra…
High Sensitivity Assay Development on the LSA®
https://carterra-bio.com/resources/high-sensitivity-assay-development-on-the-lsa/…detection (LOD) levels comparable to or more sensitive than conventional labelled techniques such as Enzyme-Linked Immunosorbent Assay (ELISA). In this example, a commercially available ELISA reagent kit for the measurement…
University of Manchester Adds Carterra’s LSA Instrument for High-Throughput Antibody Screening and Characterization
https://carterra-bio.com/news/university-of-manchester-adds-carterras-lsa-instrument-for-high-throughput-antibody-screening-and-characterization/…and fastest biologic ever to reach clinical trials: https://www.science.org/doi/full/10.1126/scitranslmed.abf1906 The Gates-funded global COVID-19 Immunotherapy Consortium (CoVIC) used the LSA to help identify the most potent antibody drug candidates from all…
La Jolla Institute for Immunology Acquires LSA Platform
https://carterra-bio.com/news/la-jolla-institute-for-immunology-acquires-lsa-platform/…in a complex matrix is also now best-in-class. “We’re proud to see the benefit of Carterra’s LSA platform being brought to bear for global good,” says Tim Germann, Chief Commercial…
Carterra is streamlining the arduous process of screening new life-saving drugs
https://carterra-bio.com/news/carterra-is-streamlining-the-arduous-process-of-screening-new-life-saving-drugs/By Elainna Ciaramella Biotherapeutic drug discovery is typically complex, time-consuming, and expensive. But new technology from Carterra, a biotech company based in Salt Lake City, enables the months-long intensive drug…
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
https://carterra-bio.com/news/ipa-acquires-the-carterra-lsa-instrument-to-enhance-antibody-discovery-and-bolster-its-ai-developments/…to enrich LENSai™. VICTORIA, BRITISH COLUMBIA (CANADA), March 19, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today…
Carterra CEO, Josh Eckman, Recognized as a Rising Star by the David Eccles School of Business
https://carterra-bio.com/news/carterra-ceo-josh-eckman-recognized-as-a-rising-star-by-the-david-eccles-school-of-business/…times faster than existing platforms, compressing months of work into days and addressing a significant bottleneck in drug discovery. Under Josh’s leadership, the Company recently raised $10M from Telegraph Hill…